Answers are grounded in this paper and cite their sources.
Targeting BTK alters IgA production and microbiota in type 1 diabetes, indicating changes in mucosal immunity.
Description IgA is an important mediator of immune-microbe interactions in the gut. It is unknown how B cell signaling protein Bruton’s Tyrosine Kinase (BTK) contributes to mucosal immunity. We previously found that Btk-deficiency selectively eliminates autoreactive B cells and autoantibodies, preventing type 1 diabetes (T1D) development in non-obese diabetic (NOD) mice. This disease protection is microbiome dependent; Akkermansia muciniphila (A.M.) is consistently increased in Btk-/-NOD mice protected against T1D. To test whether loss of Btk allowed improved colonization of A.M., we rederived Btk-/-NOD and WT NOD mice in a germ-free environment and monocolonized half the mice with A.M. At 12-15 weeks of age, some mice were sacrificed to evaluate IgA-A.M. interactions. B cells from small intestinal Peyer’s Patches were isolated, and single B cells were cultured, yielding supernatants containing monoclonal antibodies hypothesized to bind A.M. Several A.M.-binding antibodies have been identified. These will be utilized in future studies evaluating how IgA-binding modulates A.M. B cell receptor sequencing was also performed to investigate how Btk-deficiency alters the mucosal B cell repertoire. In the small intestine, Btk-deficiency decreased IgA production and IgA-coating of A.M. Moreover, A.M. prevented the development of T1D in Btk-/-NOD mice. Together, these findings demonstrate that targeting BTK alters mucosal immunology and IgA production, with downstream effects on T1D pathogenesis.
No takes yet. Share an insight, caveat, or question.
Olin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: